Georgia Department of Community Health (GDCH)
&
SXC Health Solutions

Opportunities for Pharmaceutical Manufacturer Input on Clinical Recommendations and Clinical Management Strategies by the Drug Utilization Review Board

SXC Clinical Information and Clinical Management Strategies relevant to the quality of care management for the GDCH Medicaid, PeachCare, State Health Benefit, and Board of Regents Health Plans will be presented to the Drug Utilization Review Board at each meeting. Manufacturer input on recommendations is welcomed and appreciated with these opportunities.

Recommendation Based Opportunity:

DUR Board Meeting Process: SXC Clinical Information for discussion will be posted to the GDCH web site 30 days prior to DURB meetings. Manufacturer comments and input specific to the drugs under review are made in writing directly to SXC and reported as appropriate by SXC at subsequent DURB meetings.

Ongoing Opportunity:

Manufacturers' Forum: A forum prior to each DURB meting whereby manufacturers may present:

1) Clinical information relevant to SXC information under review or drugs up for review by the DURB

2) Clinical information relevant to ongoing SXC Clinical Management Strategy development (e.g. review of drug benefit-plan designs, new drugs coming to market, new drug indications, etc.)

Upon review of SXC Clinical Information, the DURB makes recommendations to GDCH

Opportunity for Appeal to GDCH:

GDCH Review Process: DURB recommendations are reviewed by GDCH. Manufacturers that view the DURB recommendations as adverse may request an appeal meeting for review directly with GDCH, within 10 business days following DURB meetings.
Contact : Rose Duncan 404-657-7247